Results of multivariate analysis for the cumulative incidence of VZV disease and PHN
| . | SHR (95% CI) . | P . |
|---|---|---|
| Cumulative incidence of VZV | ||
| Old strategy (vs New strategy) | 2.5 (1.5-4.1) | <.01 |
| Significant GVHD* (yes/no) | 0.8 (0.5-1.3) | .37 |
| PBSC (vs other graft type) | 0.9 (0.7-1.3) | .64 |
| Matched sibling (vs other donor type) | 0.9 (0.6-1.4) | .60 |
| Cumulative incidence of PHN | ||
| Old strategy (vs New strategy) | 13.4 (1.5-120.8) | .02 |
| Significant GVHD* (yes/no) | 1.4 (0.5-3.8) | .56 |
| PBSC (vs other graft type) | 0.8 (0.2-2.7) | .70 |
| Matched sibling (vs other donor type) | 0.9 (0.3-2.7) | .90 |
| . | SHR (95% CI) . | P . |
|---|---|---|
| Cumulative incidence of VZV | ||
| Old strategy (vs New strategy) | 2.5 (1.5-4.1) | <.01 |
| Significant GVHD* (yes/no) | 0.8 (0.5-1.3) | .37 |
| PBSC (vs other graft type) | 0.9 (0.7-1.3) | .64 |
| Matched sibling (vs other donor type) | 0.9 (0.6-1.4) | .60 |
| Cumulative incidence of PHN | ||
| Old strategy (vs New strategy) | 13.4 (1.5-120.8) | .02 |
| Significant GVHD* (yes/no) | 1.4 (0.5-3.8) | .56 |
| PBSC (vs other graft type) | 0.8 (0.2-2.7) | .70 |
| Matched sibling (vs other donor type) | 0.9 (0.3-2.7) | .90 |
CI, confidence interval.
Significant GVHD onset preceded VZV disease onset in all patients in the new and old strategy groups.